Gambro Medical Device Company Intelligence Report

Date: February 7, 2013
Pages: 22
Price:
US$ 515.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: GA3DB45F921EN
Leaflet:

Download PDF Leaflet

Gambro Medical Device Company Intelligence Report
Gambro was founded in 1964 and has approximately 7,500 employees, 13 production facilities in nine countries and sales subsidiaries in more than 100 countries.

Sweden's Wallenberg family controls Gambro through its Investor AB investment firm. In June 2006, the family took over Gambro from the Stockholm Stock Exchange, in a transaction valued at approximately US$5.4 billion. The Wallenbergs previously owned 19.9% of the company before they made the purchase with EQT Partners, a Stockholm-based buyout firm partly-owned by Investor AB. As at January 2013, EQT Partners owned 51% of Gambro and Investor AB held the remaining 49% (Investor AB also owns 10% of Gambro through its investment in EQT). Gambro represents 3% of Investor AB’s total assets.

In December 2004, Gambro sold its US healthcare clinics to rival DaVita for US$3.1 billion.

In November 2006, Gambro's businesses were split into three independent businesses: Gambro Renal Products, to make products for dialysis machines and provide blood purification for hospital intensive care units; Gambro BCT, to sell blood collection and separation equipment; and Gambro Healthcare, to operate healthcare facilities in Europe, South America, Asia and Australia. Gambro Renal Products subsequently became the new Gambro AB, while Gambro BCT changed its name to CaridianBCT. In May 2007, Gambro Healthcare was sold to Bridgepoint, a European private equity firm, and is now known as Diaverum; and, in April 2011, CaridianBCT was sold to Terumo Corporation for US$2.63 billion.

In May 2011, Gambro moved its corporate headquarters from Stockholm to Lund, citing that the move will lead to improved cross-functional collaboration and efficiency improvements. The majority of Gambro’s functions, including sales and marketing, R&D and manufacturing, are present at Gambro’s Lund site, which has approximately 800 employees. The Stockholm office closed at the end of 2011.

In December 2012, Investor AB and EQT entered into a definitive agreement to sell Gambro to Baxter International, for total consideration of SKr 26.5 billion (approximately US$4.0 billion). With a broad and complementary dialysis product portfolio, Baxter can accelerate product sales in established markets such as Europe, where Gambro has an extensive footprint. Baxter could also expand Gambro's reach in high-growth regions of Latin America and Asia-Pacific, where Baxter has steadily grown its peritoneal dialysis business.

Within the healthcare industry, Investor also owns Mölnlycke Health Care, a provider of single-use surgical and wound care products and services; and Aleris, a Scandinavian healthcare and care service provider. EQT owns Dako Denmark, which undertakes medical tests used to diagnose cancer.

This company report provides
  • Overview
    • Key contact information
    • Introduction to the company and its current activities
    • Summary of its financial performance
    • Who are the company’s major competitors?
    • Key recent events in an “at a glance” format
  • Financial Review
    • Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available)
    • Table providing in-depth five-year financial analysis
    • Employee data, including breakdown by company division and geographic location
  • Strategic Focus
    Investigates the company’s aims and its areas of focus
  • Products
    Core product areas, key brands, product approvals and launches Research and Development
    • How much has been invested in R&D?
    • Where is the research based?
    • What alliances and agreements does the company have and with whom?
  • Manufacturing and Distribution
    • Identifying the company’s manufacturing locations
    • Sales and marketing facilities
  • Agreements
    • With whom has the company reached agreements and what do they involve?
    • Key contracts awarded
  • Mergers, Acquisitions, Minority Investments and Divestments
  • Litigation
  • Key Corporate Events
OVERVIEW

Key Facts
The Swedish Healthcare Landscape

STRATEGIC FOCUS

2011-2012 Achievements
Baxter Acquisition
Espicom View

FINANCIAL REVIEW

2011 Financial Results
Key Financial Highlights 2011
Outlook
Employees

PRODUCTS

Chronic
  Haemodialysis
  Peritoneal Dialysis
  Myeloma Kidney Therapy
Acute Therapies
Ventures Division
  Vascular Access
  Water Systems

RESEARCH AND DEVELOPMENT

R&D Agreements
   Novalung
Studies and Trials
   Investigation into Chronic Inflammation in ESRD Patients
   RELIEF
   RENAL
      Early initiation may have contributed to excellent outcomes
      Study emphasises importance of assessing delivery of prescribed CRRT dose

MANUFACTURING AND DISTRIBUTION

AGREEMENTS

  Medisystems
  Source Medical (now Cardinal Health Canada)
  Dipylon Medical
  Debiotech
  DaVita
  Baxter International

MERGERS AND ACQUISITIONS

  Baxter International
  CHF Solutions
  Hemapure
  Teraklin

DIVESTITURES

  CaridianBCT
  Sale of PD Business
  US Water Business
  Blood Line Manufacturing Facility in Italy
  Gambro Healthcare
  Gambro Healthcare US
  MacGREGOR
  Thoratec
  Point Therapeutics
  Scandinavian Heart Center

LITIGATION

  Fresenius Medical Care

KEY CORPORATE EVENTS

LIST OF TABLES

Recent Key Events
Gambro - Annual Financial Data, 2007-2011
Gambro’s 2011 Market Position by Major Product Groups
Gambro – Principal Manufacturing Operations, January 2013
Agreements Summary
Mergers and Acquisitions Summary

LIST OF CHARTS

Gambro - Annual Sales and Normalised EBITDA, 2011
Gambro - HD Products Market Share, 2011
Skip to top


Ask Your Question

Gambro Medical Device Company Intelligence Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: